Table 5 Adverse events
AEs | Entire cohort (n = 58) | First-line cohort (n = 44) | Later-line cohort (n = 14) | |||
|---|---|---|---|---|---|---|
All AEs n (%) | Grade 3-4 n (%) | All AEs n (%) | Grade 3-4 n (%) | All AEs n (%) | Grade 3-4 n (%) | |
Hematologic | ||||||
Neutropenia Leukopenia Thrombocytopenia Anemia | 19 (32.8) 19 (32.8) 31 (53.4) 18 (31.0) | 10 (17.2) 3 (5.2) 2 (3.4) 1 (1.7) | 12 (27.3) 12 (27.3) 22 (50.0) 12 (27.3) | 6 (13.6) 2 (4.5) 2 (4.5) 1 (2.3) | 7 (50.0) 7 (50.0) 9 (64.3) 6 (42.9) | 4 (28.6) 1 (7.1) 0 (0) 0 (0) |
Non-hematologic | ||||||
Nausea Vomiting AST ALT TBIL Fatigue Diarrhea Sensory neuropathy | 6 (10.3) 3 (5.2) 34 (58.6) 30 (51.7) 16 (27.6) 16 (27.6) 2 (3.4) 6 (10.3) | 0 (0) 0 (0) 10 (17.2) 1 (1.7) 9 (15.5) 1 (1.7) 0 (0) 1 (1.7) | 5 (11.4) 2 (4.5) 26 (59.1) 22 (50.0) 12 (27.3) 12 (27.3) 2 (4.5) 4 (9.1) | 0 (0) 0 (0) 10 (22.7) 1 (2.3) 6 (13.6) 1 (2.3) 0 (0) 1 (2.3) | 1 (7.1) 1 (7.1) 8 (57.1) 8 (57.1) 4 (28.6) 4 (28.6) 0 (0) 2 (14.3) | 0 (0) 0 (0) 0 (0) 0 (0) 3 (21.4) 0 (0) 0 (0) 0 (0) |